Hospital Clínico San Carlos, Neurology Department, C/ Prof Martín Lagos, 28040 Madrid, Spain.
HEALTH VALUE, HE Department, C/ Virgen de Aránzazu, 21, 28034 Madrid, Spain.
J Comp Eff Res. 2023 Feb;12(2):e220193. doi: 10.2217/cer-2022-0193. Epub 2023 Jan 27.
To analyze the cost-effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed. CladT was the dominant treatment, with lower costs (-74,741 € [95% CI: -67,247; -85,661 €]) and greater effectiveness (0.1920 [95% CI: -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being cost-effective and a 94.1% chance of being dominant compared with DMF. CladT is the dominant treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain.
从西班牙国家卫生系统（NHS）的角度分析氯法拉滨片（CladT）和富马酸二甲酯（DMF）治疗复发缓解型多发性硬化症（RRMS）的成本效益。采用具有 10 年时间范围和年度马尔可夫循环的概率马尔可夫模型（二阶蒙特卡罗模拟）进行分析。CladT 是一种具有优势的治疗方法，与 DMF 相比，其成本更低（-74741 欧元[95%置信区间：-67247 欧元至-85661 欧元]），效果更好（每个患者的 0.1920 [95%置信区间：-0.1659；0.2173] QALY）。与 DMF 相比，CladT 具有 95.1%的成本效益概率和 94.1%的优势概率。与 DMF 相比，CladT 是治疗西班牙 RRMS 的优势治疗方法（成本更低，QALY 更多）。
